Evotec Se · XETR:EVT
Evotec — Investor Presentation (June 2025)
30 slides from Evotec's investor presentation, June 2025
Slide 1: General company presentation
General company presentation Scientific Operational Excellence Excellence Evotec SE, Company presentation, June 2025
Slide 2: Disclaimer
Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Sec
Slide 3: Pioneering Drug Discovery; Financials
1 Pioneering Drug Discovery 2 Financials PAGE 3
Slide 4: About us
Pioneering Drug Discovery About us Pioneering Drug Discovery Just – Evotec Biologics –better Pioneering drug discovery and development, leveraging cutting-edge monetisation of technology & assets technology, disruptive science, and AI-driven innovation. Together with World leader in developing enabl
Slide 5: New strategy – sharpened investment focus
New strategy – sharpened investment focus Building blocks for value creation Enabling partners through technology and science leadership Drug Discovery & Pre-clinical Development Just – Evotec Biologics • Target Identification to IND • World leader in developing enabling technologies for end-to-end
Slide 6: Strategy in Execution – simplifying our business model
Strategy in Execution – simplifying our business model Implementation has started Strategic shift Focus & Action Streamlining • Cleaned up portfolio - high quality, high potential assets – divested EVT 201 asset pipeline • Own asset development limited to proof points for technological innovation Op
Slide 7: Operating in highly attractive markets
Operating in highly attractive markets Outsourcing and paradigm shift as drivers for superior growth Global R&D spend Outsourcing share $ 260 bn • Global R&D spend with 3% growth 2023-2030 5-7% 40% Clinical 15% • Outsourcing trend continuing - drug discovery catching up CAGR (addressable CRO market
Slide 8: Next-generation technology improving R&D returns
Next-generation technology improving R&D returns Benefits of better prediction Step change required to produce faster, safer & better R&D outcomes $ 7.7 bn Prediction, automation, spend of TOP 20 industrialisation, AI are key Pharma on clinical trials that were terminated in 2024 Evotec leading in t
Slide 9: Growing faster than market with premium offerings
Growing faster than market with premium offerings Leading technology as drivers for superior growth Multi-Omics Market Biologics CDMO market USD bn USD bn Drivers for outperformance 15 40 30 10 >20% >10% Base market growth (“CRO essentials”) 5-7% 20 5 (Tipping point to be monitored) 10 0 0 + additio
Slide 10: Near-term biopharmaceutical market drivers
Near-term biopharmaceutical market drivers Implications • Market recovery in Demand/ Shared R&D earliest end Funding Regulation Market of 2025 • Just - Evotec Biologics with robust demand and nearshoring supply • CRO market remains • Tipping point for • Uncertainty around upsides soft at 2024 levels
Slide 11: Enhancing our commercial model
Enhancing our commercial model Targeted value proposition Our offerings Our value proposition Our commercial position 3 • Access to cutting edge technology, next-gen biology & AI Pioneering drug • Enhance drug discovery & development program Strategic partnerships & discovery & risk/ rewards sharing
Slide 12: Asset pipeline with ~€16 bn opportunity (non-risk adjusted)
Asset pipeline with ~ € 16 bn opportunity (non-risk adjusted) Re-prioritized asset pipeline an important value creation lever Pipeline priorities & targets Existing portfolio with long-term revenue upside Non-risk adjusted revenue, in € bn, excluding new pipeline building • Investments into a unique
Slide 13: Just Evotec Biologics - better monetisation of technology & assets
Just Evotec Biologics - better monetisation of technology & assets Improving operational efficiency by focusing on technology leadership and core competencies Just – Evotec Biologics today Our vision for tomorrow Intellectual Expand leadership on core technology Validated technology leadership prope
Slide 14: Levers of value creation
Levers of value creation Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence > € 50 m cost reduction by 2028 & further productivity improvement Just – Evotec Biologics –bette
Slide 15: Financials
1 Pioneering Drug Discovery 2 Financials PAGE 15
Slide 16: FY 2024: Navigating a challenging year – JEB revenue +71%
FY 2024: Navigating a challenging year – JEB revenue +71% Condensed income statement FY 2024 in € m1 FY 2024 FY 2023 Change Comments External Revenues 797.0 781.4 2% Soft Shared R&D market; temporarily more investments in late-stage assets Shared R&D 611.4 673.0 (9)% Strong growth momentum of JEB ba
Slide 17: Strong start of JEB into 2025 – Group result at €3 m adj. EBITDA
Strong start of JEB into 2025 – Group result at € 3 m adj. EBITDA Condensed income statement Q1 2025 in € m1 Q1 2025 Q1 2024 Change Comments External Revenues 200.0 208.7 (4)% In-line with group expectations Shared R&D 140.6 155.2 (9)% Shared R&D softer than expected Just – Evotec Biologics (JEB)2 5
Slide 18: Liquidity developing as expected, with headroom after loan draw down
Liquidity developing as expected, with headroom after loan draw down Quarterly liquidity development Net debt, in € m 117 173 164 43 107 • Draw down of existing R&D financing facility (€ 44 m) Liquidity at 510 compensated part of cash outflow quarter end, from operating and investing in € m activiti
Slide 19: Solid funding profile
Solid funding profile Streamlined financing mix, 2% Financing strategy Share of liabilities & lease 24% obligations − Conservative fix/floating mix 39% € 439 m − Well balanced maturity Research Financing profile; +50% at ≥5Y Promissory Note − Low financing costs secured Project Financing 35% Lease o
Slide 20: Priority Reset – savings target reached
Priority Reset – savings target reached EBITDA contribution of Reset measures Recurring adj. EBITDA impact, in € m • De-prioritisation of non-core business Savings Exit of gene therapy and large-scale API manufacturing (in Halle) completed target reached • Reduced footprint >40 Non-core − Site exits
Slide 21: 2025 incremental cost out initiatives on track
2025 incremental cost out initiatives on track Implementation progress of actively managed cost reduction Evotec FTE development measures in Shared R&D Measure Progress1 Just - Evotec Biologics • Remaining Priority Reset initiatives implemented • Cologne site closed end of February 2025 Shared R&D •
Slide 22: Guidance 2025
Guidance 2025 FY 2024 Guidance 2025 Comment 5%-10% growth driven by strong JEB segment; Shared R&D in soft market Group revenues € 797 m € 840 - 880 m environment pivoting towards high- value offering Further prioritisation of scalable R&D expenditure1 € 51 m € 40 - 50 m tech-platforms and technolog
Slide 23: Commitment to operational excellence
Commitment to operational excellence Creating a sustainable cost base long-term Key levers to be addressed (short to mid-term) COGS Structural cost reset, overcapacity, footprint and processes SG&A Reduce complexity, standardisation, from admin to >€ 50 m business value Total cost out by 2028, produ
Slide 24: Mid-term Outlook
Mid-term Outlook 2028 aspiration Revenue Adj. EBITDA CAGR1 margin 2024-2028 2028 8-12% >20% (FY 2024: € 797 m) (FY 2024: ~3%) Drivers Market recovery, Operating leverage, Differentiation, Mix/Value add-ons, Value add-ons Productivity, Cost optimisation PAGE 24 1 CAGR = Compound annual growth rate
Slide 25: Appendix
Appendix PAGE 25
Slide 26: Experienced management team with long-term mission
Experienced management team with long-term mission The management team Experience Experience • 2017 – 2022 CEO of Mediq • 2018 – 2024: • 2005 – 2017 Various CFO of Mediq leadership positions at Linde • 2016 – 2017: Group, since 2007 member CFO of GE Mining of the Group Executive • 2001 – 2016: Commi
Slide 27: Global view and deep experience for best governance
Global view and deep experience for best governance Independent and diverse Supervisory Board • Since 2014 Member of • Since 2019 Member of the • Since 2022 Member of Evotec’s Evotec’s Supervisory Board Supervisory Board Supervisory Board (2021 Chairperson) (2021 Vice Chairperson) • Since 2013, Diff
Slide 28: Sustainable growth enabled by commitment, culture, values & people
Sustainable growth enabled by commitment, culture, values & people Sustainability at Evotec Our People Our Partners Safe work environment High governance standards and effective structures Diversity, equity, and inclusion Stakeholders‘ engagement Animal welfare and bioethics Our Patients Our Values
Slide 29: Shareholders supporting sustainable growth
Shareholders supporting sustainable growth Shareholder structure1 ~ 8% Novo Holdings A/S ~ 7% Mubadala Investment Company ~ 10% Triton GP HoldCo SARL ~ 75% Free float Number of shares: Listings: 52 week high/low: 177.8 m Frankfurt Stock Exchange (MDAX, TecDAX), Ticker: EVT € 10.62/€ 5.06 NASDAQ Glob
Slide 30: Volker Braun, Investor Relations & ESG
Volker Braun EVP Global Head of Investor Relations & ESG +49 (0) 40 228 999 338 (direct) +49 (0) 151 1940 5058 (mobile) [email protected]